171 related articles for article (PubMed ID: 17376008)
1. Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites.
Flotte TR; Conlon TJ; Poirier A; Campbell-Thompson M; Byrne BJ
Hum Gene Ther; 2007 Mar; 18(3):245-56. PubMed ID: 17376008
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.
Brantly ML; Spencer LT; Humphries M; Conlon TJ; Spencer CT; Poirier A; Garlington W; Baker D; Song S; Berns KI; Muzyczka N; Snyder RO; Byrne BJ; Flotte TR
Hum Gene Ther; 2006 Dec; 17(12):1177-86. PubMed ID: 17115945
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method.
Chulay JD; Ye GJ; Thomas DL; Knop DR; Benson JM; Hutt JA; Wang G; Humphries M; Flotte TR
Hum Gene Ther; 2011 Feb; 22(2):155-65. PubMed ID: 20812844
[TBL] [Abstract][Full Text] [Related]
4. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.
Arruda VR; Fields PA; Milner R; Wainwright L; De Miguel MP; Donovan PJ; Herzog RW; Nichols TC; Biegel JA; Razavi M; Dake M; Huff D; Flake AW; Couto L; Kay MA; High KA
Mol Ther; 2001 Dec; 4(6):586-92. PubMed ID: 11735343
[TBL] [Abstract][Full Text] [Related]
5. Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid α-glucosidase.
Conlon TJ; Erger K; Porvasnik S; Cossette T; Roberts C; Combee L; Islam S; Kelley J; Cloutier D; Clément N; Abernathy CR; Byrne BJ
Hum Gene Ther Clin Dev; 2013 Sep; 24(3):127-33. PubMed ID: 24021025
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.
Flotte TR; Trapnell BC; Humphries M; Carey B; Calcedo R; Rouhani F; Campbell-Thompson M; Yachnis AT; Sandhaus RA; McElvaney NG; Mueller C; Messina LM; Wilson JM; Brantly M; Knop DR; Ye GJ; Chulay JD
Hum Gene Ther; 2011 Oct; 22(10):1239-47. PubMed ID: 21609134
[TBL] [Abstract][Full Text] [Related]
7. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector.
Conlon TJ; Cossette T; Erger K; Choi YK; Clarke T; Scott-Jorgensen M; Song S; Campbell-Thompson M; Crawford J; Flotte TR
Mol Ther; 2005 Nov; 12(5):867-75. PubMed ID: 16085464
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults.
Flotte TR; Brantly ML; Spencer LT; Byrne BJ; Spencer CT; Baker DJ; Humphries M
Hum Gene Ther; 2004 Jan; 15(1):93-128. PubMed ID: 14965381
[TBL] [Abstract][Full Text] [Related]
9. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.
Brantly ML; Chulay JD; Wang L; Mueller C; Humphries M; Spencer LT; Rouhani F; Conlon TJ; Calcedo R; Betts MR; Spencer C; Byrne BJ; Wilson JM; Flotte TR
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16363-8. PubMed ID: 19706466
[TBL] [Abstract][Full Text] [Related]
10. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors.
Song S; Embury J; Laipis PJ; Berns KI; Crawford JM; Flotte TR
Gene Ther; 2001 Sep; 8(17):1299-306. PubMed ID: 11571566
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects.
Song S; Scott-Jorgensen M; Wang J; Poirier A; Crawford J; Campbell-Thompson M; Flotte TR
Mol Ther; 2002 Sep; 6(3):329-35. PubMed ID: 12231168
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector.
Lu Y; Choi YK; Campbell-Thompson M; Li C; Tang Q; Crawford JM; Flotte TR; Song S
J Gene Med; 2006 Jun; 8(6):730-5. PubMed ID: 16518879
[TBL] [Abstract][Full Text] [Related]
13. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.
Mueller C; Chulay JD; Trapnell BC; Humphries M; Carey B; Sandhaus RA; McElvaney NG; Messina L; Tang Q; Rouhani FN; Campbell-Thompson M; Fu AD; Yachnis A; Knop DR; Ye GJ; Brantly M; Calcedo R; Somanathan S; Richman LP; Vonderheide RH; Hulme MA; Brusko TM; Wilson JM; Flotte TR
J Clin Invest; 2013 Dec; 123(12):5310-8. PubMed ID: 24231351
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle.
Toromanoff A; Chérel Y; Guilbaud M; Penaud-Budloo M; Snyder RO; Haskins ME; Deschamps JY; Guigand L; Podevin G; Arruda VR; High KA; Stedman HH; Rolling F; Anegon I; Moullier P; Le Guiner C
Mol Ther; 2008 Jul; 16(7):1291-9. PubMed ID: 18461055
[TBL] [Abstract][Full Text] [Related]
15. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction.
Nakai H; Thomas CE; Storm TA; Fuess S; Powell S; Wright JF; Kay MA
J Virol; 2002 Nov; 76(22):11343-9. PubMed ID: 12388694
[TBL] [Abstract][Full Text] [Related]
16. Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice.
Song S; Goudy K; Campbell-Thompson M; Wasserfall C; Scott-Jorgensen M; Wang J; Tang Q; Crawford JM; Ellis TM; Atkinson MA; Flotte TR
Gene Ther; 2004 Jan; 11(2):181-6. PubMed ID: 14712302
[TBL] [Abstract][Full Text] [Related]
17. Intrapleural administration of an AAVrh.10 vector coding for human α1-antitrypsin for the treatment of α1-antitrypsin deficiency.
Chiuchiolo MJ; Kaminsky SM; Sondhi D; Hackett NR; Rosenberg JB; Frenk EZ; Hwang Y; Van de Graaf BG; Hutt JA; Wang G; Benson J; Crystal RG
Hum Gene Ther Clin Dev; 2013 Dec; 24(4):161-73. PubMed ID: 24191907
[TBL] [Abstract][Full Text] [Related]
18. Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin.
Ye GJ; Budzynski E; Sonnentag P; Miller PE; Sharma AK; Ver Hoeve JN; Howard K; Knop DR; Neuringer M; McGill T; Stoddard J; Chulay JD
Hum Gene Ther Clin Dev; 2015 Sep; 26(3):165-76. PubMed ID: 26390090
[TBL] [Abstract][Full Text] [Related]
19. Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle.
Löser P; Hillgenberg M; Arnold W; Both GW; Hofmann C
Gene Ther; 2000 Sep; 7(17):1491-8. PubMed ID: 11001369
[TBL] [Abstract][Full Text] [Related]
20. Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice.
Lu Y; Tang M; Wasserfall C; Kou Z; Campbell-Thompson M; Gardemann T; Crawford J; Atkinson M; Song S
Hum Gene Ther; 2006 Jun; 17(6):625-34. PubMed ID: 16776571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
